A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The researchers are doing this study to find out whether combining 177Lu-PSMA-617 with SBRT
is a safe and effective treatment in people who have hormone-sensitive oligometastatic
prostate cancer. The researchers also want to learn more about how the study treatment
affects daily life and the symptoms of cancer. This study is the first to test the
combination of 177Lu-PSMA-617 and SBRT in people.